Teva receives tentative FDA nod for generic idiopathic pulmonary fibrosis treatment
Teva Pharmaceutical Industries (TEVA) received tentative approval from the FDA for generic pirfenidone. The drug candidate is aimed towards treating idiopathic pulmonary fibrosis. The tentative approval implies that the application fulfilled the requirements of the approval. However, patent issues are required to be resolved before a full approval is given.
Teva, one of the most prominent generic drug companies in the world, also recently announced its new collaboration for strengthening its foothold in the United States market. The company has inked a